The letters make reference to the results of the CORTICUS trial to question the use of prolonged glucocorticoid treatment in patients with H1N1-induced acute lung injury (ALI)-acute respiratory distress syndrome (ARDS). We wish to address the reader to two recent comprehensive meta-analyses on prolonged glucocorticoid treatment in severe sepsis (*n* = 1,228) \[[@CR1]\] and ALI-ARDS (*n* = 648) \[[@CR2]\], and the recommendation of a consensus statement \[[@CR3]\]. Despite the overall significant reduction in mortality \[[@CR1], [@CR2]\], we do not disagree with the writers, that the question of a mortality benefit for either sepsis or ARDS can be opened to contrasting opinions with merits. Nonetheless, these meta-analyses \[[@CR1], [@CR2]\] have concluded that prolonged low-to-moderate dose glucocorticoid treatment is (a) safe and (b) associated with significant reduction in organ dysfunction scores, duration of intensive care unit (ICU) stay (4.5 days for sepsis \[[@CR1]\] and 7 days for ARDS \[[@CR4]\]) and mechanical ventilation (6.6 days for ARDS \[[@CR4]\]).

Our work provides initial evidence that a low----in comparison to the broad dosage used in the SARS experience----daily glucocorticoid dose \[[@CR3]\] is safe and effective. These findings have provided proof of concept for the design of an ongoing French randomized trial in patients with severe pneumonia caused by H1N1 (Dr. Annane's personal communication). Similar to the SARS epidemic, prolonged glucocorticoid treatment was widely used in the Canadian (51%) and Australian (69%) experiences. However, data on patient population (shock, respiratory failure, etc.), dosage/duration, or subgroup analysis for evaluating possible benefits are not available.

Dr. Salluh's statement that the "story of anti-inflammatory therapies in severe infections has been so far a story of disenchantment" is disputed by the findings of meta-analyses on prolonged glucocorticoid treatment in severe sepsis \[[@CR1]\], ALI-ARDS, \[[@CR2]\] *Pneumocystis jiroveci* pneumonia, bacterial and tuberculous meningitis, tuberculous pericarditis, severe typhoid fever, and tetanus \[[@CR5]\]. Effectiveness in ARDS caused by viral (varicella zoster virus, Hantavirus, etc.,) and fungal (blastomycosis and histoplasmosis) pneumonia was previously presented.

The hydrocortisone dosage and duration was dictated by the work of Confalonieri's and others as described in the text. An aggregate of small-randomized trials (*n* = 198; including subgroup analyses) of patients with severe pneumonia requiring ICU admission----many with shock and/or ALI-ARDS----found a significant reduction in short-term mortality with little heterogeneity (RR = 0.40, 95% CI 0.18--0.89, *P* = 0.03, *I* ^*2*^ 12%).\[[@CR1], [@CR2]\]. The Veteran Administration Cooperative Studies Program has recently funded a large (*n* = 1,420) randomized trial to investigate the effects of prolonged low-dose methylprednisolone treatment \[extended steroid (in) CAP(e)----ESCAPe\] in patients admitted to the ICU with severe CAP. The primary end-point of the trial is 60 days all-cause mortality.

Ventilator management (as described in the text) conformed to ARDSnet recommendations maintaining plateau pressure ≤30 cm H~2~O. One single episode of pneumothorax was observed. Secondary prophylaxis with infection surveillance was implemented (as described in the text) in agreement with recent recommendations \[[@CR4]\]. Table [1](#Tab1){ref-type="table"} provides median values for SOFA score with nonparametric statistics. The conclusions of our study do not change.Table 1Findings by day 7 and outcome variablesVariablesCombined (*N* = 13)H1N1 rRT-PCRSevere ARDSPositive (*N* = 8)Negative (*N* = 5)*P* valueYes (*N* = 6)No (*N* = 7)*P* valueC-reactive protein day 7 (mg/dl)^a^38.9 (50.1)38.9 (55.1)24.5 (42.4)0.5149.5 (66.4)34.2 (18.9)0.32Lung injury score (LIS) on day 72.0 (1.2)2.0 (0.7)2.0 (1.3)0.712.70 (0.75)1.75 (0.50)0.06APACHE II score on day 78.0 (4.0)7.5 (6.5)8.0 (2.0)0.469.0 (10.0)7.0 (3.0)0.11SOFA score on day 7^b^3.0 (1.0)3.0 (2.0)2.0 (2.0)0.413.0 (3.0)2.0 (2.0)0.21Serum creatine kinase----U/l^a^170 (673)185 (441)107 (1,182)1.0139 (1,154)200 (238)0.71Duration of mechanical ventilation (days)12.0 (7.0)12.0 (5.5)7.0 (7.0)0.3814.0 (3.0)7.0 (6.0)0.03Duration of corticosteroid treatment (days)21.0 (9.0)24.5 (9.5)20.0 (6.0)0.4227.5 (7.0)18.0 (11.0)0.05ICU length of stay (days)14.0 (8.0)14.0 (7.5)8.0 (7.0)0.2715.5 (3.0)10.0 (6.0)0.11Hospital length of stay (days)15.0 (10.0)18.5 (11.5)14.0 (3.0)0.3121.0 (8.0)13 (5.0)0.13Data are reported as median and interquartile range^a^ Missing values: *1* C-reactive protein levels (1 H1N1 positive) and *2* serum creatine kinase (2 H1N1 negative)^b^ Includes SOFA score correction (as noted in Table [1](#Tab1){ref-type="table"}) for worst PaO~2~:FiO~2~ scores
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